Actively Recruiting
Registry of Autoimmune Interstitial Lung Disease
Led by EPIMAR registry · Updated on 2022-05-06
1000
Participants Needed
1
Research Sites
285 weeks
Total Duration
On this page
Sponsors
E
EPIMAR registry
Lead Sponsor
S
Sociedad Argentina de Reumatologia
Collaborating Sponsor
AI-Summary
What this Trial Is About
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma. In recent years, with the advent of new diagnostic tools and therapeutic options, multidisciplinary evaluation is essential, since it optimizes the interpretation of each case and the quality of care for these pathologies Consensus for the identification and management of ILD associated with SSc (ILD-SSc) is the only guideline published at present. In the others autoimmune ILD (Ai-ILD), screening, diagnosis, treatment and follow-up strategies are usually performed according to the criteria of the treating medical team. Guidelines regarding the follow-up and indication of immunosuppressive and antifibrotic treatment are lacking. Many questions on the horizon of the Ai-ILD should be answered as better quality evidence emerges from studies with a greater number of patients and better methodological design.
CONDITIONS
Official Title
Registry of Autoimmune Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of interstitial lung disease within the last 5 years confirmed by a multidisciplinary team including at least one pulmonologist and one rheumatologist
- Lung abnormalities on high-resolution computed tomography within the last 12 months, including ground glass opacities, consolidations, reticulations, traction bronchiectasis, or honeycomb
- One of the following: established or early connective tissue disease; interstitial pneumonia with autoimmune features (IPAF) by ATS/ERS 2015 criteria; or ANCA positivity confirmed by immunofluorescence and ELISA, with or without systemic vasculitis
- Spirometry performed within the last 6 months before joining the study
- Voluntary signing of informed consent
You will not qualify if you...
- Unable to complete clinical follow-up or required studies as per protocol
- Unable to be evaluated by a multidisciplinary team including at least a rheumatologist and a pulmonologist
- Interstitial lung disease caused by a non-autoimmune reason as determined by the multidisciplinary team (e.g., occupational or toxic causes)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Epimar Ii
Buenos Aires, Argentina
Actively Recruiting
Research Team
F
Florencia Vivero, MD
CONTACT
J
Juan Enghelmayer, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here